comparative data in available tkis for hcc
Published 5 years ago • 30 plays • Length 8:23Download video MP4
Download video MP3
Similar videos
-
6:20
response and outcomes with tkis in hcc
-
5:40
multitargeted tki therapy in metastatic hcc
-
4:24
optimal use of second-line tkis in hepatocellular carcinoma
-
13:51
how to integrate new agents in hcc: the role of tkis
-
7:35
checkpoint inhibitors versus tki therapy in hcc
-
6:42
selecting frontline multikinase inhibition in hcc
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc
-
3:35
emerging multikinase inhibitors in hcc
-
2:24
emerging i-o combination trials in unresectable hcc
-
6:10
asco 2020 data for treatment of advanced hcc
-
7:14
proactive management of tki side effects in hcc
-
19:09
harnessing the kinome: multi-kinase inhibitors for the management of hepatocellular carcinoma
-
5:26
hcc whiteboard #1: the epidemiology of hepatocellular carcinoma and current standard of care
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
6:02
evolution of systemic therapy in hcc
-
12:39
velocity vlog: role of tkis in hepatocellular carcinoma - recent updates
-
9:52
factors in selecting immunotherapy or tki inhibition
-
1:03
the role of tkis in the management of hepatocellular carcinoma